Optimal monitoring for onset of mivacurium chloride blockade.
The purpose of this article is to determine the optimal monitoring for onset of neuromuscular blockade as it relates to mivacurium, a new short-acting nondepolarizing neuromuscular blocker. Clinically, mivacurium has a higher percentage of undesirable consequences to tracheal intubation such as: diaphramatic movement, coughing, and purposeful movement. It is important to understand the time line from onset to recovery with mivacurium and the best muscle to determine onset blockade to minimize these unwanted effects.
D016903:Drug Monitoring / Q000379:methods*; D004558:Electric Stimulation; D006801:Humans; D007442:Intubation, Intratracheal; D007546:Isoquinolines / Q000627:therapeutic use*; D000077590:Mivacurium; D003473:Neuromuscular Nondepolarizing Agents / Q000627:therapeutic use*
D007546:Isoquinolines; D003473:Neuromuscular Nondepolarizing Agents; D000077590:Mivacurium